DBV Technologies S.A. (DBV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DBV Technologies S.A. (DBV) has a cash flow conversion efficiency ratio of -0.236x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-49.10 Million ≈ $-57.40 Million USD) by net assets (€207.90 Million ≈ $243.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See DBV days of operational coverage to measure how many days the company can operate on defensive assets alone.
DBV Technologies S.A. - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how DBV Technologies S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
DBV Technologies S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DBV Technologies S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bonheur
OL:BONHR
|
0.082x |
|
Arafura Rare EARTHS Ltd
AU:ARU
|
-0.014x |
|
Suzhou Medsys Tech Co Ltd
SHG:603990
|
0.021x |
|
Juewei Food Co Ltd
SHG:603517
|
0.020x |
|
Sichuan Xunyou Network Technology Co Ltd
SHE:300467
|
0.041x |
|
Inversiones Aguas Metropolitanas SA
SN:IAM
|
0.039x |
|
Jiangxi Yuean Advanced Materials Co Ltd
SHG:688786
|
0.056x |
|
Foshan Golden Milky Way Intelligent Equipment Co Ltd
SHE:300619
|
0.173x |
Annual Cash Flow Conversion Efficiency for DBV Technologies S.A. (2011–2025)
The table below shows the annual cash flow conversion efficiency of DBV Technologies S.A. from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see DBV market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €168.79 Million ≈ $197.33 Million |
€-126.12 Million ≈ $-147.45 Million |
-0.747x | +80.41% |
| 2024-12-31 | €27.39 Million ≈ $32.02 Million |
€-104.47 Million ≈ $-122.14 Million |
-3.815x | -571.38% |
| 2023-12-31 | €140.19 Million ≈ $163.89 Million |
€-79.65 Million ≈ $-93.12 Million |
-0.568x | -98.41% |
| 2022-12-31 | €194.50 Million ≈ $227.39 Million |
€-55.70 Million ≈ $-65.12 Million |
-0.286x | +73.74% |
| 2021-12-31 | €99.27 Million ≈ $116.06 Million |
€-108.24 Million ≈ $-126.55 Million |
-1.090x | -65.92% |
| 2020-12-31 | €252.01 Million ≈ $294.62 Million |
€-165.61 Million ≈ $-193.61 Million |
-0.657x | +12.28% |
| 2019-12-31 | €218.05 Million ≈ $254.92 Million |
€-163.34 Million ≈ $-190.96 Million |
-0.749x | +33.50% |
| 2018-12-31 | €165.78 Million ≈ $193.81 Million |
€-186.74 Million ≈ $-218.32 Million |
-1.126x | -28.02% |
| 2017-12-31 | €182.88 Million ≈ $213.81 Million |
€-160.91 Million ≈ $-188.12 Million |
-0.880x | -258.89% |
| 2016-12-31 | €267.90 Million ≈ $313.21 Million |
€-65.68 Million ≈ $-76.79 Million |
-0.245x | -195.04% |
| 2015-12-31 | €384.24 Million ≈ $449.21 Million |
€-31.93 Million ≈ $-37.33 Million |
-0.083x | +53.34% |
| 2014-12-31 | €182.22 Million ≈ $213.04 Million |
€-32.45 Million ≈ $-37.94 Million |
-0.178x | +45.72% |
| 2013-12-31 | €74.09 Million ≈ $86.61 Million |
€-24.31 Million ≈ $-28.42 Million |
-0.328x | -23.20% |
| 2012-12-31 | €66.84 Million ≈ $78.15 Million |
€-17.80 Million ≈ $-20.81 Million |
-0.266x | +49.14% |
| 2011-12-31 | €19.79 Million ≈ $23.13 Million |
€-10.36 Million ≈ $-12.11 Million |
-0.524x | -- |
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobu… Read more